

Supplementary Table 6. 4-MC increases repopulation ability in cisplatin-treated mice, 4 weeks after transplantation.

Treatment	Percentage of donor engraftment	RU per 10⁵ BMNC	Estimated RU per femur
Saline	41.51 ± 4.37 ^{&}	0.76 ± 0.13	40.87 ± 6.85
Saline + 4 MC	31.84 ± 4.22 ^{&}	0.5 ± 0.1	22.64 ± 4.43
Cisplatin	30.79 ± 3.56 ^{&*}	0.47 ± 0.08	7.04 ± 1.2
Cisplatin + 4-MC	66.37 ± 4.93	2.56 ± 0.64	54.11 ± 9.69

For this analysis 10⁵ BMNC (CD45.1⁺) purified from saline, saline + 4-MC, cisplatin or cisplatin + 4-MC treated mice 4 weeks after transplantation were mixed with 10⁵ BMNC CD45.2⁺ competitor cells and transplanted into CD45.2⁺ recipients; 16 weeks later the percentage of donor (CD45.1⁺) cells in the blood was determined by flow cytometry and the repopulating unit (RU) frequency calculated (n=6-8). *p<0.05 when compared to saline-treated mice; [&]p<0.05 when compared to cisplatin + 4-MC treated mice. Please note that to reduce the number of experimental mice used, the experiments shown in table S2 and S5 were performed simultaneously. Hence saline or cisplatin-treated mice in table S2 are the same as those in table S5.